Prevention of Candida infection in neonates
- Mohan Pammi, MD, PhD
Mohan Pammi, MD, PhD
- Associate Professor
- Baylor College of Medicine
Candida is a major cause of neonatal infection in preterm infants, especially in extremely low and very low birth weight infants [1-4]. Successful management of neonatal candidiasis requires effective treatment of Candida infection with appropriate antifungal therapy and supportive care, and preventive measures to reduce the risk of systemic Candida infections.
The prevention of Candida infections in neonates will be reviewed here. The clinical manifestations, diagnosis, etiology, risk factors and treatment of neonatal candidal infections are discussed separately. (See "Clinical manifestations and diagnosis of Candida infection in neonates" and "Epidemiology and risk factors for Candida infection in neonates" and "Treatment of Candida infection in neonates".)
Prevention of systemic candidal infections in neonates is important because of the poor clinical outcome of neonates with candidemia. Prevention efforts have focused on the very low birth weight (VLBW, BW <1500 g) and extremely low birth weight (ELBW, BW <1000 g) infants who are at the highest risk for invasive candidal infections. (See "Epidemiology and risk factors for Candida infection in neonates", section on 'Epidemiology' and "Epidemiology and risk factors for Candida infection in neonates", section on 'Risk factors for invasive candidiasis'.)
Preventive management includes general measures that can be applied broadly to all infants in the neonatal intensive care unit; and administration of prophylactic antifungal agents, which is reserved for ELBW infants who are cared for in NICUs with a high baseline rate of systemic fungal infection.
General measures are focused upon reducing cross-infection of Candida in the neonatal intensive care unit (NICU) and risk factors that increase the likelihood of candidemia. These include:To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504.
- Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13:1110.
- Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002; 110:285.
- Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006; 117:1680.
- Silverman J, Vazquez JA, Sobel JD, Zervos MJ. Comparative in vitro activity of antiseptics and disinfectants versus clinical isolates of Candida species. Infect Control Hosp Epidemiol 1999; 20:676.
- Mohan P, Eddama O, Weisman LE. Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units. Cochrane Database Syst Rev 2007; :CD006068.
- Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319.
- Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119.
- Kaufman DA. Challenging issues in neonatal candidiasis. Curr Med Res Opin 2010; 26:1769.
- Campbell JR, Zaccaria E, Baker CJ. Systemic candidiasis in extremely low birth weight infants receiving topical petrolatum ointment for skin care: a case-control study. Pediatrics 2000; 105:1041.
- Kaufman D. Strategies for prevention of neonatal invasive candidiasis. Semin Perinatol 2003; 27:414.
- Austin N, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2013; :CD003478.
- Sims ME, Yoo Y, You H, et al. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988; 5:33.
- Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. Mycoses 2006; 49:484.
- Wainer S, Cooper PA, Funk E, et al. Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr Infect Dis J 1992; 11:713.
- Mersal A, Alzahrani I, Azzouz M, et al. Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial. J Clin Neonatol 2013; 2:88.
- Austin N, Cleminson J, Darlow BA, McGuire W. Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database Syst Rev 2015; :CD003478.
- Benjamin DK Jr, Hudak ML, Duara S, et al. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. JAMA 2014; 311:1742.
- Cleminson J, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev 2015; :CD003850.
- Kaufman DA, Cuff AL, Wamstad JB, et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011; 158:759.
- Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660.
- Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.
- Kaufman DA. Why prevent invasive Candida infections? J Perinatol 2008; 28:385.
- Healy CM, Baker CJ. Fluconazole prophylaxis in the neonatal intensive care unit. Pediatr Infect Dis J 2009; 28:49.
- Manzoni P, Mostert M, Jacqz-Aigrain E, Farina D. The use of fluconazole in neonatal intensive care units. Arch Dis Child 2009; 94:983.
- Leonart LP, Tonin FS, Ferreira VL, et al. Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis. J Pediatr 2017.
- Greenberg RG, Benjamin DK Jr, Gantz MG, et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr 2012; 161:264.
- Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011; 31:63.
- Manzoni P, Stolfi I, Messner H, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012; 129:116.